Performance Analysis of Beximco Pharmaceuticals Ltd.
Royal Roads University, Canada
Dhaka Study Centre
Assignment
Course Name: BUSA 530 Corporate Finance
Submitted to: Mr. Mokdum Morshed
Title of the Assignment:
PERFORMANCE ANALYSIS OF BEXIMCO PHARMACEUTICALS LTD.
Submitted By: Md. Fazlul Haque
Executive Summary
This report prepared to make a through analysis of the financial statements of Beximco Pharmaceuticals Ltd (BPL). The report mainly highlights the results of various ratio analysis of the company. In order to make the analysis more informative, inter-firm comparisons have also been provided by performing ratio analysis of other leading pharmaceutical companies in Bangladesh. It is hoped that the report would provide a reliable & effective insight into the performance of the particular company.
Beximco Pharmaceuticals Ltd. is a leading edge pharmaceutical company and is a member of the BEXIMCO Group, the largest private sector industrial conglomerate in Bangladesh. The company’s strategic strengths include strong recognition of its brands, highly skilled work force and diversified business mix. BPL started its operation in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA and now have grown to become nation's one of the leading pharmaceutical companies, supplying more than 10% of country's total medicine need. Today Beximco Pharma manufactures and markets its own `branded generics' for almost all diseases from AIDS to cancer, from infection to asthma, from hypertension to diabetes for both national and international markets.
Beximco Pharmaceuticals Ltd. Manufacture in several world-class manufacturing plants, ensuring high quality standards complying with the World Health Organization (WHO) approved current Good Manufacturing Practices (cGMP). BPL also contract manufacture for major international brands of leading multinational companies.
The recipient of three times `gold' national export trophy, Beximco Pharma is the
Dhaka Study Centre
Assignment
Course Name: BUSA 530 Corporate Finance
Submitted to: Mr. Mokdum Morshed
Title of the Assignment:
PERFORMANCE ANALYSIS OF BEXIMCO PHARMACEUTICALS LTD.
Submitted By: Md. Fazlul Haque
Executive Summary
This report prepared to make a through analysis of the financial statements of Beximco Pharmaceuticals Ltd (BPL). The report mainly highlights the results of various ratio analysis of the company. In order to make the analysis more informative, inter-firm comparisons have also been provided by performing ratio analysis of other leading pharmaceutical companies in Bangladesh. It is hoped that the report would provide a reliable & effective insight into the performance of the particular company.
Beximco Pharmaceuticals Ltd. is a leading edge pharmaceutical company and is a member of the BEXIMCO Group, the largest private sector industrial conglomerate in Bangladesh. The company’s strategic strengths include strong recognition of its brands, highly skilled work force and diversified business mix. BPL started its operation in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA and now have grown to become nation's one of the leading pharmaceutical companies, supplying more than 10% of country's total medicine need. Today Beximco Pharma manufactures and markets its own `branded generics' for almost all diseases from AIDS to cancer, from infection to asthma, from hypertension to diabetes for both national and international markets.
Beximco Pharmaceuticals Ltd. Manufacture in several world-class manufacturing plants, ensuring high quality standards complying with the World Health Organization (WHO) approved current Good Manufacturing Practices (cGMP). BPL also contract manufacture for major international brands of leading multinational companies.
The recipient of three times `gold' national export trophy, Beximco Pharma is the